CBAR provides statistical leadership and expertise to collaborative research networks in HIV and other infectious diseases in the United States and internationally. This includes representing the Statistical and Data Analysis Center (SDAC) and the Data and Operations Center (DOC) for the following research networks:
The ACTG is an international cooperative clinical trials group dedicated to research in the treatment of HIV/AIDS, and the treatment and prevention of co-infections and other co-morbidities that affect HIV-infected people, notably tuberculosis and viral hepatitis. The ACTG is primarily funded by the National Institute of Allergy and Infectious Diseases (NIAID), with funding from other NIH Institutes including NCI and NIMH.
The IMPAACT Network is an international cooperative clinical trial groups dedicated to research in the treatment of children and adolescents with HIV/AIDS, its complications, and other infectious diseases that affect HIV-infected people, notably tuberculosis. It also has a major focus on research to prevent mother-to-child transmission of HIV. IMPAACT is primarily funded by the NIAID and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
The PHACS network conducts observational cohort studies which focus on evaluating long-term outcomes in: a) infants exposed to perinatal antiretroviral therapy (ART) to prevent mother-to-child HIV transmission (PMTCT), and b) perinatally HIV-infected and perinatally HIV-exposed uninfected children, adolescents, and young adults as they mature. The PHACS network is primarily funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), with co-funding from NIAID, NIMH, NIAAA, NIDCR, NINDS, NIDCD, and NIDA.
Other research projects include:
- The Biostatistical Core for the Harvard University Center for AIDS Research (CFAR)
- The Botswana Harvard AIDS Institute Partnership (BHP)
- The NIAID Influenza Research Collaboration (IRC)
- Data Coordinating Center for the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
- A Phase III randomized clinical trial of maternal antiviral prophylaxis to prevent perinatal transmission of hepatitis B virus in Thailand